Last updated: February 13, 2026
What Is the Market Outlook for NDC 00168-0015?
NDC 00168-0015 refers to Hepatitis C Virus (HCV) treatment, specifically a formulation of Sofosbuvir and Ledipasvir. This combination is marketed as Harvoni by Gilead Sciences. It is an established therapy for chronic hepatitis C infection, with FDA approval since 2014.
Market Size and Demand for Ledipasvir/Sofosbuvir
The hepatitis C market has experienced significant growth since the introduction of direct-acting antivirals (DAAs). The global demand is influenced by several factors:
- Prevalence of hepatitis C: Approximately 58 million people worldwide, with high prevalence in Egypt, Pakistan, and parts of the US.
- Treatment adoption: Increasing screening programs and the push for eradication target higher treatment rates.
- Approval and reimbursement policies: Coverage varies across regions, affecting patient access.
In 2022, the global hepatitis C drug market was valued at approximately $8 billion, with DAAs accounting for more than 75% of this. Gilead's Harvoni holds a significant share, although competition from generics and other DAAs has increased.
Competitive Landscape
- Brand drugs: Harvoni (Gilead), Epclusa (Gilead), Zepatier (Merck), Mavyret (AbbVie) collectively control the majority of prescriptions.
- Generics: Several generic versions have entered markets, especially in countries with price controls, reducing Gilead’s market share.
Price Projections and Trends
Current Pricing
- United States: The list price for a 12-week course of Harvoni is roughly $94,500.
- Negotiated prices: Due to insurance and rebate programs, actual costs to payers are often below list prices, averaging around $54,000–$80,000 per course.
Price Dynamics and Future Trends
- Generics and biosimilars: Entry is causing downward pressure on prices in low- and middle-income countries.
- Market consolidation: As older therapies phase out, newer regimens with shorter durations and fewer side effects provide competitive advantages.
- Pricing adjustments: Gilead has announced tiered pricing strategies, lowering prices in emerging markets to expand access.
Price Projections (2023–2028)
| Year |
Estimated Price Range per Treatment Course |
Key Factors |
| 2023 |
$40,000 – $80,000 |
Continued generic competition, negotiations |
| 2024 |
$35,000 – $75,000 |
Increased biosimilar penetration |
| 2025 |
$30,000 – $70,000 |
Market saturation, patent expirations |
| 2026 |
$25,000 – $60,000 |
Broader availability of lower-cost options |
| 2027 |
$20,000 – $55,000 |
Volume-driven pricing, new generics |
| 2028 |
$15,000 – $50,000 |
Increased generics, market maturity |
Regulatory and Policy Impact
- Patent expirations: Gilead’s primary patents for Harvoni are set to expire around 2028–2029 in key markets, opening pathways for biosimilar competition.
- Pricing regulations: Governments in the UK, India, and parts of Europe are pushing for lower drug prices, accelerating downward pricing trends.
Key Factors Influencing the Market
- Patent landscape: Patent expirations will significantly influence price decline.
- Generic entry: Entry of lower-cost generics in emerging markets will expand access.
- Technological advancements: Shorter, more tolerable regimens could shift demand patterns.
- Reimbursement policies: Budget constraints and negotiations impact achievable prices.
Conclusions
The hepatitis C therapy market, especially for NDC 00168-0015, is characterized by declining prices driven by patent expirations and increased generics. While prices remain high in developed markets, expect a gradual reduction aligned with biosimilar entry, regulatory pressures, and market competition. The opportunity for volume increases exists in low- and middle-income countries as prices decline.
Key Takeaways
- The global hepatitis C drug market was valued at around $8 billion in 2022.
- Gilead’s Harvoni dominates early treatment but faces increasing generic competition.
- Prices are projected to decline from an average of $40,000–$80,000 in 2023 to below $20,000 in 2028.
- Patent expirations by 2028–2029 will accelerate generic entry and price erosion.
- Access expansion in emerging markets will hinge on regulatory and reimbursement policies.
FAQs
Q1: When will patent protections for Harvoni expire?
A1: Patents are set to expire in the US and Europe around 2028–2029, opening markets for biosimilars.
Q2: What is the potential global market for generic versions of this drug?
A2: Generics could capture a significant share in emerging markets, potentially reaching over 50% of the volume in low-income regions by 2030.
Q3: How do pricing strategies vary across regions?
A3: Developed markets maintain higher list prices due to lack of price controls, while negotiations and tiered pricing reduce costs in emerging markets.
Q4: What are the key competitive threats to Harvoni?
A4: Cheaper oral regimens with shorter durations, fewer side effects, and broader-spectrum activity, such as Mavyret and Epclusa, are rivals.
Q5: How does market saturation impact future pricing?
A5: As most eligible patients are treated, demand growth slows, pushing prices further downward due to increased competition.
Sources:
[1] IQVIA Disease & Asset Analytics (2022). Hepatitis C Market Data.
[2] Gilead Sciences Annual Reports (2022).
[3] European Medicines Agency (EMA). Patents and exclusivity data.
[4] World Health Organization. Global Hepatitis Report (2019).
